Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective
Section snippets
Background
As in most industrialised countries, pharmaceutical expenditures – as well as total expenditures for health care – have grown rapidly in Sweden [1], [2]. The reasons for this are a continuing development of new and expensive pharmaceuticals [3] for a greying population. In Sweden, the total costs for pharmaceuticals doubled between 1990 and 2001. This increase was more than in any other OECD country [4]. The cost increase was particularly rapid for outpatient prescription pharmaceuticals
Methods
Nine case studies, where each county council was a case, were carried out using qualitative and descriptive methods [13]. After a survey among the county councils of models developed for handling the responsibility for costs of prescription pharmaceuticals, the nine county councils were selected based on their method of decentralization and their progress in the work with the development of the models. The remaining twelve county councils had either not developed a model (10) or had just
Decentralization models
Two main models for decentralization of responsibility for prescription drugs within the PBS were found: a population based and a prescriber based. In the population based model, family medicine in primary care was responsible for costs of pharmaceuticals classified as “basic drugs” regardless of prescriber. “Basic drugs” constituted approximately 80% of the costs of prescription drugs in each county council with a population based model. Each county council did its own classification of
Discussion
In Sweden, the county councils have full responsibility for financing and provision of health care. However, prior to the reforms subsidies for outpatient pharmaceuticals were paid by the state and incentives for the county councils for cost containment were lacking. In reality, outpatient prescription pharmaceuticals were a free utility for the county councils and their physicians. When cost containing incentives are missing, it is likely that prescription decisions to a larger extent are made
Conclusions
Under a system of third party payment patients do not face the full opportunity cost of their use of pharmaceuticals. In systems like this the problems of moral hazard has to be managed otherwise other parts of health care have to face cutbacks. However, as long as the use of pharmaceuticals is cost effective and prioritised in competition with other treatment interventions increased pharmaceutical expenditures do not need to be a problem in itself. The decentralization of the responsibility
Acknowledgement
This study is part of a larger project that was funded by grants from the Västra Götaland region. The performance and design of the study was conducted independent of the funding organisation. The authors have no conflicts of interest to declare.
References (26)
- et al.
Pharmaceutical expenditure in Sweden
Health Policy
(1999) - et al.
Cost and utilisation of pharmaceuticals in Sweden
Health Policy
(1997) - et al.
Comparative experience in home care and pharmaceutical policy
Health Policy
(1997) Is decentralisation the real solution? A three country study
Health Policy
(2006)- et al.
Unintended effects of a cost-containment policy: results of a natural experiment in Germany
Social Science and Medicine
(1997) Management of cost and utilization of pharmaceuticals in Germany
Health Policy
(1997)- et al.
What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?
Health Policy
(1998) - et al.
Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding?
Health Policy
(2000) - et al.
The new pharmaceutical policy in Italy
Health Policy
(1998) Pricing and reimbursement of drugs in Sweden
European Journal of Health Economics
(2002)
Why did drug spending increase during the 1990s? A decomposition based on Swedish data
Pharmacoeconomics
Strategies to improve the cost effectiveness of general practitioner prescribing. An international perspective
Pharmacoeconomics
Cited by (12)
Ten years experience with models for financing of outpatient prescriptions
2013, Health Policy and TechnologyCitation Excerpt :In order to collect information on the usefulness of the models in practice, we selected to approach county councils that had made early choices on policies for the financing of medicines. The sample consisted of the same participating county councils as in the study performed in 2003 [11]. The rest of the county councils in Sweden had not at that time implemented a distinctive responsibility for pharmaceutical costs and were thus not included in the initial sampling.
Pharmaceutical policies: Effects of financial incentives for prescribers
2015, Cochrane Database of Systematic ReviewsPharmaceutical SNorway and Sweden
2015, Pharmaceutical Prices in the 21st CenturyAdministration of government subsidies using contactless bank cards
2014, ICEIS 2014 - Proceedings of the 16th International Conference on Enterprise Information SystemsNationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden
2011, Annals of the Rheumatic DiseasesSmall-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009
2011, Scandinavian Journal of Rheumatology